Stryker (SYK) Receives “Buy” Rating from Royal Bank of Canada

Royal Bank of Canada reaffirmed their buy rating on shares of Stryker (NYSE:SYK) in a report published on Tuesday. The firm currently has a $175.00 price objective on the medical technology company’s stock.

A number of other equities research analysts have also commented on the company. Robert W. Baird upgraded Stryker from a neutral rating to an outperform rating and increased their price target for the stock from $161.00 to $173.00 in a research report on Thursday, November 16th. Zacks Investment Research lowered Stryker from a hold rating to a sell rating in a research report on Monday, October 16th. BMO Capital Markets upgraded Stryker to a market perform rating and set a $163.00 price target on the stock in a research report on Tuesday, December 12th. JPMorgan Chase & Co. upgraded Stryker from a neutral rating to an overweight rating in a research report on Tuesday, January 2nd. Finally, Stifel Nicolaus upped their price objective on Stryker from $158.00 to $168.00 and gave the stock a buy rating in a report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company. Stryker currently has a consensus rating of Hold and a consensus price target of $156.60.

Stryker (NYSE SYK) traded down $1.24 during midday trading on Tuesday, reaching $159.54. The company had a trading volume of 1,241,800 shares, compared to its average volume of 1,150,000. The company has a market cap of $59,710.00, a price-to-earnings ratio of 34.02, a PEG ratio of 2.30 and a beta of 0.78. Stryker has a 1-year low of $119.05 and a 1-year high of $164.20. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.02. The business had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. Stryker’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.39 EPS. research analysts anticipate that Stryker will post 6.47 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Friday, December 29th will be issued a dividend of $0.47 per share. This is an increase from Stryker’s previous quarterly dividend of $0.43. The ex-dividend date is Thursday, December 28th. This represents a $1.88 annualized dividend and a yield of 1.18%. Stryker’s dividend payout ratio is currently 40.09%.

In other news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $155.34, for a total value of $776,700.00. Following the transaction, the insider now owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 7.40% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of SYK. Acrospire Investment Management LLC acquired a new position in shares of Stryker in the 2nd quarter valued at $111,000. Motco lifted its stake in shares of Stryker by 50.7% in the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock valued at $115,000 after purchasing an additional 278 shares during the period. Sit Investment Associates Inc. lifted its stake in shares of Stryker by 114.3% in the 4th quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock valued at $128,000 after purchasing an additional 440 shares during the period. San Francisco Sentry Investment Group CA lifted its stake in shares of Stryker by 47.8% in the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 325 shares during the period. Finally, Oak Point Wealth Management acquired a new position in shares of Stryker in the 4th quarter valued at $145,000. 74.90% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Stryker (SYK) Receives “Buy” Rating from Royal Bank of Canada” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://transcriptdaily.com/2018/01/11/stryker-syk-receives-buy-rating-from-royal-bank-of-canada.html.

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply